Respiratory Syncytial Virus (RSV) Vaccination Coverage, Pregnant Women, United States

Pregnant Women RSV Vaccination Coverage

Weekly RSV vaccination coverage estimates for pregnant women 18–49 years are based on electronic health record (EHR) data from the Vaccine Safety Datalink (VSD), a collaboration between CDC's Immunization Safety Office and multiple integrated health care organizations.*

The denominator includes those who reached at least 32 weeks' gestation since September 1, 2025.^† The numerator includes those who have received an RSV vaccine during pregnancy as of the week ending date.^‡ Pregnant women are not removed from the numerator or denominator when the pregnancy ends. Cumulative vaccination coverage for one week may be lower than cumulative coverage for a previous week due to the addition of pregnant women in the denominator.^§ Additionally, no requirements for length of enrollment in a VSD site are applied, and vaccinations given outside of a VSD site might not be included.^±

• Figure 6A. Percent of Pregnant Women Ages 18–49 Years Vaccinated with RSV Vaccine Overall and by Race and Ethnicity. Data Source: Vaccine Safety Datalink.
  
• Figure 6B. Percent of Pregnant Women Ages 18–49 Years Vaccinated with RSV Vaccine by Week and Race and Ethnicity. Data Source: Vaccine Safety Datalink.
  

Download Data for Figures 6A & 6B

^{Note: Data from prior seasons have been archived and can be accessed using the following links: 2023-24 Respiratory Syncytial Virus (RSV) Vaccination Coverage, Pregnant Women | RSVVaxView | CDC and 2024-25 Respiratory Syncytial Virus (RSV) Vaccination Coverage, Pregnant Women, United States | RSVVaxView | CDC. Archived 2023–24 season data are based on 8 reporting sites whereas data reported during 2024–25 season and on this dashboard include 10 reporting sites.}

^{*Naleway AL, Crane B, Irving SA, et al. Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. Ther Adv Drug Saf. 2021, Jun 14.}

^{†Pregnant women who were past the recommended window of 32-36 week's gestation prior to September 1, 2025, were removed from the denominator. The denominator may include pregnant women 32–36 weeks of pregnancy as of September 1, 2025, or later, who received an RSV vaccine during a previous pregnancy. These pregnant women are therefore not eligible for another RSV vaccine this season/pregnancy; however, their infants would be eligible to receive nirsevimab.}

^{‡Vaccinations may have been administered outside the recommended window of 32–36 weeks gestation. Frequently Asked Questions About RSV Vaccine for Pregnant Women | CDC}

^{§The coverage estimate for any given week may change as the season progresses.}

^{±Estimates presented here might underestimate RSV vaccination coverage among women enrolled in the VSD sites. Additional information on weekly estimation methodology vs. post-season estimation methodology can be found here: Influenza, COVID-19, and Respiratory Syncytial Virus (RSV) vaccination coverage among pregnant women, weekly estimation methodology vs. post-season estimation methodology, Vaccine Safety Datalink (VSD) | RespVaxView | CDC.}